Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca2+ - de novo ceramide - PP2A - ROS dependent signaling pathway

The targeted therapeutics sorafenib and vorinostat interact in a synergistic fashion to kill carcinoma cells by activating CD95, and this drug combination is entering phase I evaluation. In this study we determined how CD95 is activated by treatment with this drug combination. Low doses of sorafenib...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Park, Margaret A., Mitchell, Clint, Zhang, Guo, Yacoub, Adly, Allegood, Jeremy, Häussinger, Dieter, Reinehr, Roland, Larner, Andrew, Spiegel, Sarah, Fisher, Paul B., Voelkel-Johnson, Christina, Ogretmen, Besim, Grant, Steven, Dent, Paul
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2918282/
https://ncbi.nlm.nih.gov/pubmed/20631069
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-10-0999
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados